RET-话题@MedSci

#RET#

170篇内容 | 3623人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1913943, encodeId=6ae3191394313, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌, objectType=article, longId=204067, objectId=48f320406e75, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48f320406e75, replyNumber=0, likeNumber=101, createdTime=2021-01-10, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48f320406e75, moduleTitle=创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48f320406e75)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913948, encodeId=ffbd191394830, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据, objectType=article, longId=209638, objectId=e44b2096389c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44b2096389c, replyNumber=0, likeNumber=114, createdTime=2021-09-15, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44b2096389c, moduleTitle=RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e44b2096389c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913946, encodeId=60e819139461b, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Gastrointest Endosc：Barrett食管发展成食管肿瘤的风险！, objectType=article, longId=206920, objectId=c6b020692027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6b020692027, replyNumber=0, likeNumber=81, createdTime=2021-10-04, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6b020692027, moduleTitle=Gastrointest Endosc：Barrett食管发展成食管肿瘤的风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6b020692027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913947, encodeId=51c3191394e30, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择, objectType=article, longId=208973, objectId=b4c72089e345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4c72089e345, replyNumber=0, likeNumber=63, createdTime=2021-07-25, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4c72089e345, moduleTitle=基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4c72089e345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913938, encodeId=607e191393872, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗, objectType=article, longId=199973, objectId=8ec51999e38c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ec51999e38c, replyNumber=0, likeNumber=70, createdTime=2020-09-05, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ec51999e38c, moduleTitle=NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ec51999e38c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913942, encodeId=c91b19139427f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Aging Cell：致癌性RET竟然会引起头发变白 , objectType=article, longId=203202, objectId=b0da2032025c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0da2032025c, replyNumber=0, likeNumber=73, createdTime=2021-06-17, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0da2032025c, moduleTitle=Aging Cell：致癌性RET竟然会引起头发变白 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0da2032025c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913940, encodeId=43a3191394071, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=基石药业RET抑制剂普拉替尼中国上市申请获受理并纳入优先审评, objectType=article, longId=200377, objectId=e4512003e762, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4512003e762, replyNumber=0, likeNumber=80, createdTime=2021-03-24, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4512003e762, moduleTitle=基石药业RET抑制剂普拉替尼中国上市申请获受理并纳入优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4512003e762)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913929, encodeId=59371913929f7, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后, objectType=article, longId=196602, objectId=6b09196602cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b09196602cb, replyNumber=0, likeNumber=49, createdTime=2020-09-30, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b09196602cb, moduleTitle=Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b09196602cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913927, encodeId=295a191392e3f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益, objectType=article, longId=194393, objectId=2d8619439350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d8619439350, replyNumber=0, likeNumber=81, createdTime=2020-06-12, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d8619439350, moduleTitle=FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d8619439350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913932, encodeId=376f191393257, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Clin cancer research：多参数MR-RET成像可预测复发性高级别神经胶质瘤对GDC-0084治疗的反应性, objectType=article, longId=197009, objectId=bd7b19e00943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd7b19e00943, replyNumber=0, likeNumber=85, createdTime=2020-12-23, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd7b19e00943, moduleTitle=Clin cancer research：多参数MR-RET成像可预测复发性高级别神经胶质瘤对GDC-0084治疗的反应性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd7b19e00943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913924, encodeId=12cc1913924de, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=FDA批准了针对RET基因突变或融合癌症的药物--Retevmo, objectType=article, longId=193857, objectId=f26b19385e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26b19385e5c, replyNumber=0, likeNumber=82, createdTime=2020-10-16, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26b19385e5c, moduleTitle=FDA批准了针对RET基因突变或融合癌症的药物--Retevmo, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f26b19385e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913931, encodeId=976a191393198, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Blood：RET激活可改善造血干细胞的存活和扩增, objectType=article, longId=196942, objectId=ba831969429a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba831969429a, replyNumber=0, likeNumber=57, createdTime=2020-08-31, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba831969429a, moduleTitle=Blood：RET激活可改善造血干细胞的存活和扩增, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba831969429a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913923, encodeId=1ce319139230d, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=近年Barrett食管研究进展，要点来了！, objectType=article, longId=191200, objectId=294519120081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=294519120081, replyNumber=0, likeNumber=76, createdTime=2021-02-09, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=294519120081, moduleTitle=近年Barrett食管研究进展，要点来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=294519120081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913922, encodeId=8edf191392218, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=PureTech通过减少纤维化和炎症来治疗淋巴水肿的候选药LYT-100，其临床试验首位参与者开始接受治疗, objectType=article, longId=189496, objectId=66d91894967c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66d91894967c, replyNumber=0, likeNumber=75, createdTime=2020-08-30, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66d91894967c, moduleTitle=PureTech通过减少纤维化和炎症来治疗淋巴水肿的候选药LYT-100，其临床试验首位参与者开始接受治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66d91894967c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913939, encodeId=d409191393972, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=J Endod：RET后牙根发育的定量评估：一项系统性文献回顾和meta分析, objectType=article, longId=200231, objectId=b3fa2002310f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3fa2002310f, replyNumber=0, likeNumber=72, createdTime=2021-01-25, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3fa2002310f, moduleTitle=J Endod：RET后牙根发育的定量评估：一项系统性文献回顾和meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3fa2002310f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913925, encodeId=8513191392517, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=FDA：礼来口服RET抑制剂selpercatinib在美国上市, objectType=article, longId=193914, objectId=5fd0193914a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fd0193914a4, replyNumber=0, likeNumber=0, createdTime=2020-12-10, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fd0193914a4, moduleTitle=FDA：礼来口服RET抑制剂selpercatinib在美国上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fd0193914a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913928, encodeId=cdf319139285f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性, objectType=article, longId=195474, objectId=2d9e1954e445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d9e1954e445, replyNumber=0, likeNumber=65, createdTime=2021-03-10, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d9e1954e445, moduleTitle=Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d9e1954e445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913918, encodeId=1d1319139183d, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=FDA接受ST-001 nanoFenretinide治疗T细胞淋巴瘤的新药申请, objectType=article, longId=185189, objectId=1979185189ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1979185189ec, replyNumber=0, likeNumber=70, createdTime=2020-02-29, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1979185189ec, moduleTitle=FDA接受ST-001 nanoFenretinide治疗T细胞淋巴瘤的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1979185189ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913917, encodeId=eefd191391eed, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Combretastatin A1联合阿糖胞苷治疗复发性急性髓细胞白血病成人患者中取得积极结果, objectType=article, longId=185151, objectId=1a4f18515140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a4f18515140, replyNumber=0, likeNumber=87, createdTime=2020-07-15, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a4f18515140, moduleTitle=Combretastatin A1联合阿糖胞苷治疗复发性急性髓细胞白血病成人患者中取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a4f18515140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913935, encodeId=188319139352d, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=NATURE: 异染色质动态变化影响Rett综合征患者神经发育, objectType=article, longId=197948, objectId=68a419e948b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68a419e948b0, replyNumber=0, likeNumber=96, createdTime=2021-07-02, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68a419e948b0, moduleTitle=NATURE: 异染色质动态变化影响Rett综合征患者神经发育, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68a419e948b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

RET

2020-05-29

ysjykql (审核中...)

前往app查看评论内容

#RET#

创新靶向药RET抑制剂Pralsetinib扩展适应症获美国FDA批准，用于治疗甲状腺癌

2021-01-10

ysjykql (审核中...)

前往app查看评论内容

#RET#

RET抑制剂TPX-0046治疗肿瘤，I/II期SWORD-1期研究已取得初步临床数据

2021-09-15

ysjykql (审核中...)

前往app查看评论内容

#RET#

Gastrointest Endosc：Barrett食管发展成食管肿瘤的风险！

2021-10-04

ysjykql (审核中...)

前往app查看评论内容

#RET#

基石药业宣布中国选择性RET抑制剂普吉华®（普拉替尼胶囊）获批，为肺癌患者提供治疗新选择

2021-07-25

ysjykql (审核中...)

前往app查看评论内容

#RET#

NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗

2020-09-05

ysjykql (审核中...)

前往app查看评论内容

#RET#

Aging Cell：致癌性RET竟然会引起头发变白

2021-06-17

ysjykql (审核中...)

前往app查看评论内容

#RET#

基石药业RET抑制剂普拉替尼中国上市申请获受理并纳入优先审评

2021-03-24

ysjykql (审核中...)

前往app查看评论内容

#RET#

Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后

2020-09-30

ysjykql (审核中...)

前往app查看评论内容

#RET#

FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益

2020-06-12

ysjykql (审核中...)

前往app查看评论内容

#RET#

Clin cancer research：多参数MR-RET成像可预测复发性高级别神经胶质瘤对GDC-0084治疗的反应性

2020-12-23

ysjykql (审核中...)

前往app查看评论内容

#RET#

FDA批准了针对RET基因突变或融合癌症的药物--Retevmo

2020-10-16

ysjykql (审核中...)

前往app查看评论内容

#RET#

Blood：RET激活可改善造血干细胞的存活和扩增

2020-08-31

ysjykql (审核中...)

前往app查看评论内容

#RET#

近年Barrett食管研究进展，要点来了！

2021-02-09

ysjykql (审核中...)

前往app查看评论内容

#RET#

PureTech通过减少纤维化和炎症来治疗淋巴水肿的候选药LYT-100，其临床试验首位参与者开始接受治疗

2020-08-30

ysjykql (审核中...)

前往app查看评论内容

#RET#

J Endod：RET后牙根发育的定量评估：一项系统性文献回顾和meta分析

2021-01-25

ysjykql (审核中...)

前往app查看评论内容

#RET#

FDA：礼来口服RET抑制剂selpercatinib在美国上市

2020-12-10

ysjykql (审核中...)

前往app查看评论内容

#RET#

Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性

2021-03-10

ysjykql (审核中...)

前往app查看评论内容

#RET#

FDA接受ST-001 nanoFenretinide治疗T细胞淋巴瘤的新药申请

2020-02-29

ysjykql (审核中...)

前往app查看评论内容

#RET#

Combretastatin A1联合阿糖胞苷治疗复发性急性髓细胞白血病成人患者中取得积极结果

2020-07-15

ysjykql (审核中...)

前往app查看评论内容

#RET#

NATURE: 异染色质动态变化影响Rett综合征患者神经发育

2021-07-02

科室
- - 订阅+
  - 更多科室
工具
服务